approved glp 1 agonists GLP-1 receptor A clinician's perspective 📝 GLP-1

A spokesperson from Pfizer outlined the incident to Tides Global

Effect of dipeptidyl peptidase-4 inhibitors on bone metabolism and the possible underlying mechanisms

The review further highlights emergent research on "next-generation" therapies with weight-loss efficacy of up to about 24% in clinical trials, approaching weight-loss magnitudes reported in some surgical interventions

(1) (2) This peptide mimics GLP-1 but lasts much longer in the body, making it a valuable blueprint for modern medications

The cost for obesity drugs with list prices in the $1,000 to $1,350 range per month before insurance is a major roadblock for many patients who could benefit from significant weight loss and the reduced potential for related health issues

These drugs are anticipated to overcome the challenges of oral semaglutide, most notably the substantial food-drug interactions and low oral bioavailability (0.4% to 1.0%)